VISTOGARD- uridine triacetate granule

País: Estados Unidos

Língua: inglês

Origem: NLM (National Library of Medicine)

Ingredientes ativos:

uridine triacetate (UNII: 2WP61F175M) (uridine - UNII:WHI7HQ7H85)

Disponível em:

Wellstat Therapeutics Corporation

DCI (Denominação Comum Internacional):

uridine triacetate

Composição:

uridine triacetate 951 mg in 1 g

Via de administração:

ORAL

Tipo de prescrição:

PRESCRIPTION DRUG

Indicações terapêuticas:

VISTOGARD® is indicated for the emergency treatment of adult and pediatric patients: - following a fluorouracil or capecitabine overdose regardless of the presence of symptoms, or - who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration. Limitations of Use - VISTOGARD is not recommended for the non-emergent treatment of adverse reactions associated with fluorouracil or capecitabine because it may diminish the efficacy of these drugs. - The safety and efficacy of VISTOGARD initiated more than 96 hours following the end of fluorouracil or capecitabine administration have not been established. None. Risk Summary Limited case reports of uridine triacetate use during pregnancy are insufficient to inform a drug-associated risk of birth defects and miscarriage. When adminis

Resumo do produto:

VISTOGARD orange-flavored oral granules (95% w/w) are available in single-dose packets containing 10 grams of uridine triacetate. Store at USP controlled room temperature, 25°C (77°F); excursions permitted to 15° to 30 °C (59° to 86°F).

Status de autorização:

New Drug Application

Características técnicas

VISTOGARD- URIDINE TRIACETATE GRANULE
WELLSTAT THERAPEUTICS CORPORATION
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
VISTOGARD SAFELY AND EFFECTIVELY. SEE FULL
PRESCRIBING INFORMATION FOR VISTOGARD.
VISTOGARD (URIDINE TRIACETATE) ORAL GRANULES
INITIAL U.S. APPROVAL: 2015
INDICATIONS AND USAGE
VISTOGARD is a pyrimidine analog indicated for the emergency treatment
of adult and pediatric patients:
following a fluorouracil or capecitabine overdose regardless of the
presence of symptoms, or
who exhibit early-onset, severe or life-threatening toxicity affecting
the cardiac or central nervous system, and/or early-
onset, unusually severe adverse reactions (e.g., gastrointestinal
toxicity and/or neutropenia) within 96 hours following
the end of fluorouracil or capecitabine administration. (1)
Limitations of use:
VISTOGARD is not recommended for the non-emergent treatment of adverse
reactions associated with fluorouracil or
capecitabine because it may diminish the efficacy of these drugs. (1)
The safety and efficacy of VISTOGARD initiated more than 96 hours
following the end of fluorouracil or capecitabine
administration have not been established. (1)
DOSAGE AND ADMINISTRATION
Recommended Dosage
Adults: 10 grams (1 packet) orally every 6 hours for 20 doses, without
regard to meals. (2.1)
Pediatric: 6.2 grams/m of body surface area (not to exceed 10 grams
per dose) orally every 6 hours for 20 doses,
without regard to meals. See the full prescribing information for body
surface area-based dosing. (2.1)
Preparation and Administration
Pediatric: Measure the dose using either a scale accurate to at least
0.1 gram, or a graduated teaspoon accurate to ¼
teaspoon. (2.1)
Mix each VISTOGARD dose with 3 to 4 ounces of soft foods such as
applesauce, pudding or yogurt and ingest within
30 minutes of mixing. Do not chew the VISTOGARD granules. Drink at
least 4 ounces of water. (2.2)
If a patient vomits within 2 hours of taking a dose of VISTOGARD,
initiate another c